IONS
Ionis Pharmaceuticals, Inc.NASDAQHealthcare$74.79-0.45%ClosedMarket Cap: $12.35B
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
24.77
P/S
13.10
EV/EBITDA
3.22
DCF Value
$-92.46
FCF Yield
-2.6%
Div Yield
0.0%
Margins & Returns
Gross Margin
98.3%
Operating Margin
-40.5%
Net Margin
-40.4%
ROE
-68.8%
ROA
-10.8%
ROIC
-12.0%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $203.0M | 96.1% | $-215.0M | $-229.0M | $-1.41 | — |
| FY 2025 | $944.0M | 98.3% | $-382.0M | $-381.0M | $-2.38 | — |
| Q3 2025 | $156.7M | 98.5% | $-160.2M | $-128.6M | $-0.80 | — |
| Q2 2025 | $452.0M | 99.1% | $139.8M | $123.6M | $0.68 | — |
| Q1 2025 | $131.6M | 98.9% | $-146.9M | $-146.9M | $-0.93 | — |
| Q4 2024 | $226.6M | 98.3% | $-110.8M | $-104.3M | $-0.66 | — |
| FY 2024 | $705.1M | 98.4% | $-475.1M | $-453.9M | $-3.04 | — |
| Q3 2024 | $133.8M | 99.2% | $-148.7M | $-140.5M | $-0.95 | — |
| Q2 2024 | $225.3M | 98.2% | $-66.1M | $-66.3M | $-0.45 | — |
| Q1 2024 | $119.5M | 98.2% | $-149.5M | $-142.8M | $-0.98 | — |
| Q4 2023 | $324.5M | 99.1% | $-6.1M | $-9.3M | $-0.06 | — |
| FY 2023 | $787.6M | 98.8% | $-353.7M | $-366.3M | $-2.56 | — |